New WRN inhibitors reported in Laekna Pharmaceutical patent

June 26, 2026

Laekna Pharmaceutical Ningbo Co. Ltd. has disclosed Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors found to be potentially useful for the treatment of cancer.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Illustration of red and white blood cells in an artery

Case report links APOLD1 variant to vascular-type bleeding disorder

BioWorld Science

Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...